Abstract: The present invention relates to a method for producing optically active IHOG, which can in turn be used for the production of monatin. The present invention further relates to a method for producing optically active monatin, and aldolase used for these methods. As such, the present invention enables the synthesis of 4-(Indole-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid with high optical purity, which is useful as an intermediate in the synthesis of optically active monatin, from indole pyruvic acid and pyruvic acid (or oxaloacetic acid).

Abstract: Optically active amine derivatives are produced by acting on imine derivatives with a culture of microorganisms having the ability to stereoselectively reduce the compounds, microbial cells, or processed products thereof, followed by collecting the generated optically active amine derivatives. Optically active amine derivatives obtained in the present invention are useful as materials for pharmaceutical agents. The present invention enables, for example, production of an optically active compound represented by formula (IV): (wherein R group represents an alkyl group having one to three carbon atoms; and n represents an integer of 1 to 4).

Abstract: The present invention is to provide an industrially advantageous method for producing an amino acid derivative. Provided is a method for producing an amino acid derivative including contacting a microorganism and/or an enzyme with a hydroxyimino acid represented by the following general formula (I): wherein R1 represents an optionally substituted predetermined hydrocarbon group; R2 represents a C1 to C3 alkyl group or a hydrogen atom; and n is 0 or 1, to produce an amino acid derivative represented by the following general formula (III): wherein R1 and n have the same meanings as those of R1 and n in the general formula (I), wherein the microorganism and/or the enzyme is capable of catalyzing the reaction.

Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.

Abstract: The invention relates to a method for preparing ?-caprolactam comprising deacylating N-acyl-6-aminocaproic acid and forming ?-caprolactam. The deacylation may be carried out chemically or biocatalytically. The invention further relates to a host cell, comprising a recombinant vector comprising a nucleic acid sequence encoding an enzyme capable of catalysing the formation of 6-aminocaproic acid from N-acyl-6-aminocaproic acid.

Abstract: The present invention is directed to a method utilizing a microorganism with reduced isocitrate dehydrogenase activity for the production of fine chemicals. Said fine chemicals may be amino acids, monomers for polymer synthesis, sugars, lipids, oils, fatty acids or vitamins and are preferably amino acids of the aspartate family, especially methionine or lysine, or derivatives of said amino acids, especially cadaverine. Furthermore, the present invention relates to a recombinant microorganism having a reduced isocitrate dehydrogenase activity in comparison to the initial microorganism and the use of such microorganisms in producing fine chemicals such as aspartate family amino acids and their derivatives.

Abstract: Methods for preferentially hydrolyzing one stereoisomer of an isoxazoline diester over another, as well as an enzyme for facilitating the preferential hydrolysis are provided. Also provided are methods for providing mixtures of (RR) and (RS) monatin as well as (SS) and (SR) monatin, which methods can include the step of stereoselectively hydrolyzing an isoxazoline diester.

Abstract: The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, method of using the engineered ketoreductase enzymes to synthesize a variety of chirally pure compounds, and the chirally pure compounds prepared therewith.

Abstract: The invention relates to a method for preparing ?-caprolactam comprising reducing the carbon-carbon double bond of (Z)-6,7-dihydro-1H-azepin-2(5H)-one, wherein the reduction is catalysed by a biocatalyst. The invention further relates to a novel host cell comprising a biocatalyst capable of catalysing said reduction and to a novel polynucleotide encoding a biocatalyst capable of catalysing said reduction.

Abstract: Aspects of the invention relate to methods for the production of difunctional alkanes in host cells. In particular, aspects of the invention describe components of genes associated with the difunctional alkane production from carbohydrate feedstocks in host cells. More specifically, aspects of the invention describe metabolic pathways for the production of adipic acid, aminocaproic acid, caprolactam, and hexamethylenediamine via 2-ketopimelic acid.

Abstract: The claimed invention relates to a process for preparing (meth)acrylates of N-hydroxyalkylated amides, in which open-chain N-hydroxyalkylated amides are esterified with (meth)acrylic acid or transesterified with at least one (meth)acrylic ester in the presence of at least one heterogeneous catalyst selected from the group consisting of an inorganic salt and an enzyme.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.

Abstract: The present invention relates to macbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for the production of these compounds involving incorporation of non-natural starter units and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.

Abstract: A compound having a structure expressed by the following Structural Formula (1) and a compound having a structure expressed by the following Structural Formula (2):

Abstract: The present invention relates to a method for preparing ?-amino-?-caprolactam, comprising converting lysine to ?-amino-?-caprolactam, wherein the conversion is catalysed by a biocatalyst. Further, the invention relates to a host cell comprising at least one recombinant vector comprising a nucleic acid sequence encoding a biocatalyst with lysine cyclase activity. Further a method is provided wherein ?-amino-?-caprolactam is used for preparing c-caprolactam.

Abstract: The present invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 1; or (b) a nucleotide sequence which is the complement of SEQ ID No. 1; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 1; or (d) a nucleotide sequence having at least 85% sequence identity (preferably at least 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) with SEQ ID No. 1; or (e) a part of any one of (a) to (d), wherein said nucleic acid molecule encodes or is a complementary to a nucleic acid molecule encoding one or more polypeptides, or comprises or is complementary to a nucleic acid molecule comprising one or more genetic elements, having functional activity in the synthesis of a polyketide-based or macrolactam molecule.

Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl esters, comprising the enantioselective enzyme reduction of a 1-aryl-2-tetrazolyl-ethyl ketone to form a (R)-1-aryl-2-tetrazolyl-ethyl alcohol and the carbamation of said alcohol.

Abstract: The present invention relates to a method for preparing an adipate ester or thioester. The invention further relates to a method for preparing adipic acid from said ester or thioester. Further the invention provides a number of methods for preparing an intermediate for said ester or thioester. Further the invention relates to a method for preparing 6-amino caproic acid (6-ACA), a method for preparing 5-formyl valeric acid (5-FVA), and a method for preparing caprolactam. Further, the invention relates to a host cell for use in a method according to the invention.

Abstract: The present invention relates to 4,5-dihydromacbecin analogues to the formula (IA) or (IB), or a pharmaceutically acceptable salt there of: wherein: R1 represents H or CONH2 that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.

Abstract: The invention provides for isomerase (e.g., racemase) and epimerase polypeptides and nucleic acids encoding such polypeptides. Also provided are methods of using such isomerase (e.g., racemase) and epimerase nucleic acids and polypeptides.

Abstract: The present invention refers to a recombinant fission yeast strain useful for the improved production of human cytochrome P450s. The improvement in the cytochrome P450 rate is achieved by a coexpression of a functional human electron transfer chain e.g. CPR (cytochrome P450 reductase). The invention further relates to uses of the recombinant fission yeast and particularly the use of the recombinant fission yeast in methods to generate cytochrome P450 dependent metabolites.

Abstract: A method for producing an optically active compound includes reacting a nucleophile with a mixture of R- and S-stereoisomers of an azolide substrate by enzyme-catalyzed kinetic resolution so as to produce the optically active compound, wherein the azolide substrate contains an azole group used as a leaving group and an acyl group directly bonded to a nitrogen atom of the azole group.

Abstract: Methods and systems for increasing the production of equilibrium reactions are described. In some embodiments, a method comprises removing enzymes from a reaction mixture once equilibrium is achieved, selectively re-adding enzymes and reactants for driving the product-forming reaction to product, and optionally recycling stabilized intermediates, by-products and/or co-products back into the reaction mixture. In some embodiments, a method comprises purifying the desired product from a reaction mixture and selectively recycling one or more components of the reaction mixture, such as original reactants, intermediates, co-products or by-products back into the reaction mixture as desired to improve titer. Systems for implementing the methods are also provided. In some embodiments the methods and systems are implemented for increasing the production of monatin and monatin derivatives, produced in multi-step equilibrium pathways.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.

Abstract: The invention provides for aminotransferase and oxidoreductase polypeptides and nucleic acids encoding such polypeptides. Also provided are methods of using such aminotransferase and oxidoreductase nucleic acids and polypeptides.

Abstract: Improved constructs for increasing efficiency of transformation of thermophilic host cells for production of carbon-based products of interest and methods for producing carbon-based products of interest are provided.

Abstract: The present invention relates to ansamycin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine.

Abstract: The present invention relates to substituted heterocycles, processes for their preparation, and their use in medicaments, especially for the treatment of inflammatory disease, i.e. asthma, or cancer.

Abstract: The present invention relates to a novel bacterial strain designated DD1, which has the ability to produce organic acids, in particular succinic acid (SA), which was originally isolated from bovine rumen, and is capable of utilizing glycerol as a carbon source; and variant strains derived there from retaining said capability; as well as to methods of producing organic acids, in particular succinic acid by making use of said microorganism.

Abstract: The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.

Abstract: Disclosed is a process for producing an optically active indoline-2-cabroxylic acid or a derivative thereof, which is useful as a raw material for synthesis of pharmaceuticals or the like, from an indoline-2-cabroxylic acid in an industrially advantageous manner. An indoline-2-cabroxylic acid is converted into an N-substituted-indoline-2-carboxylic acid, and then is esterified using a biocatalyst having a stereoselectivity in an organic solvent containing an alcohol. Next, an alkali is used to obtain an optically active N-substituted-indoline-2-carboxylic acid ester and an optically active N-substituted-indoline-2-cabroxylic acid or a salt thereof, and then the two optically active substances are separated utilizing distribution properties thereof in an organic solvent/water system.

Abstract: Disclosed is a method for the preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester, comprising the asymmetric reduction of arylketone and the carbamation of alcohol.

Abstract: The present invention relates to a process for producing efficiently glutamic acid derivatives (including salts thereof) such as monatin by converting a substituted ?-keto acid of formula (1) into a glutamic acid derivative of formula (2) in the presence of an enzyme catalyzing conversion of the same.

Abstract: The present invention relates to a cell, which has been genetically modified relative to its wild type, so that in comparison with its wild type it is able to produce more ?-aminocarboxylic acids, more ?-aminocarboxylic acid esters or more lactams derived from ?-aminocarboxylic acids, starting from carboxylic acids or carboxylic acid esters. Furthermore, the present invention relates to a method for the production of a genetically modified cell, the cells obtainable by this method, a method for the production of ?-aminocarboxylic acids, of ?-aminocarboxylic acid esters or of lactams derived from ?-aminocarboxylic acids, the ?-aminocarboxylic acids, ?-aminocarboxylic acid esters or lactams derived from ?-aminocarboxylic acids obtainable by this method, a method for the production of polyamides based on ?-aminocarboxylic acids or based on lactams and the polyamides obtainable by this method.

Abstract: The invention provides a non-naturally occurring microbial organism having a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The invention additionally provides a method for producing 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid. The method can include culturing a 6-aminocaproic acid, caprolactam or hexametheylenediamine producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid.

Abstract: The invention relates to a process for preparing an enantiomerically and/or diastereomerically enriched ester or thioester having at least two adjacent chiral centres, wherein a mixture of stereoisomers of a secondary alcohol or thiol having a structure comprising a first chiral center forming a secondary alcohol or secondary thiol moiety in the beta position relative to a second chiral center having one hydrogen substituent, is reacted with an acyl donor in the presence of an epimerisation catalyst and a stereoselective acylation catalyst.

Abstract: The claimed invention relates to a process for preparing (meth)acrylates of N-hydroxyalkylated amides, in which open-chain N-hydroxyalkylated amides are esterified with (meth)acrylic acid or transesterified with at least one (meth)acrylic ester in the presence of at least one heterogeneous catalyst selected from the group consisting of an inorganic salt and an enzyme.

Abstract: 4-(indol-3-ylmethyl)-4-hydroxy-2-oxoglutarate, which is useful as an intermediate in the synthesis of monatin, may be synthesized from indole pyruvic acid and pyruvic acid (and/or oxaloacetic acid) by using a novel aldolase derived from the genus Pseudomonas, Erwinia, Flavobacterium, or Xanthomonas.

Abstract: The present invention relates to a process for producing efficiently glutamic acid derivatives (including salts thereof) such as monatin by converting a substituted ?-keto acid of formula (1) into a glutamic acid derivative of formula (2) in the presence of an enzyme catalyzing conversion of the same.

Abstract: Disclosed is a novel process for producing a compound represented by the general formula (1) by using a microorganism, wherein the compound is useful as a plant growth stimulant. Specifically disclosed is a process for producing a succinic acid amide compound represented by the general formula (1) [wherein Ar represents a phenyl, naphthyl or indolyl group which may have a substituent; and n represents a numeral value ranging from 1 to 4] or a salt thereof, which is characterized by culturing a microorganism of the genus Pseudomonas that is capable of synthesizing a succinic acid amide in a culture medium containing an arylalkylamine represented by the general formula (2).

Abstract: The present invention relates to carbamoylglycine derivatives, a process for the preparation of carbamoylglycine derivatives and the use of carbamoylglycine derivatives in the preparation of enantiomerically enriched ?-amino acids. Furthermore, the present invention relates to the preparation of pharmaceutically active products such as perindopril and ramipril using the novel carbamoylglycine derivatives.

Abstract: It is an object of the present invention to provide a procedure for realizing inexpensive and simple production of 3-indole-pyruvic acid. A transformant is made using a polynucleotide having a specific nucleotide sequence encoding a protein having an oxidase activity, and oxidase is generated by culturing the transformant in a medium to accumulate the oxidase in the medium and/or the transformant. Further, tryptophan is converted into 3-indole-pyruvic acid in the presence of the transformant and/or a culture thereof to produce 3-indole-pyruvic acid.

Abstract: The present invention provides a scalable process for producing a concentrate containing a mass of a farnesylated dibenzodiazepinone by fermenting in an aqueous culture medium a strain of a microorganism that is capable of producing the farnesylated dibenzodiazepinone, upon completion of fermentation harvesting the fermentation broth and extracting the fermentation broth to provide an extract, and thereafter treating the extract to form the concentrate. The concentrate so produced may be utilized in downstream processes for producing pharmaceutical compounds. A strain of a Micromonospora species capable of producing a farnesylated dibenzodiazepinone at a high yield rate is provided, together with culture media for culturing microorganisms, and fermentation conditions for production of the farnesylated dibenzodiazepinone of the concentrate.

Abstract: The present invention provides a simple industrial process for producing an L- or D-optically active ?-methylcysteine derivative or its salt, which is a useful pharmaceutical intermediate, from readily available, inexpensive raw materials. In a process for producing an L- or D-optically active ?-methylcysteine derivative or its salt, a racemic N-carbamoyl-?-methylcysteine derivative or its salt is D-selectively cyclized with hydantoinase to produce a D-5-methyl-5-thiomethylhydantoin derivative or its salt and an N-carbamoyl-?-methyl-L-cysteine derivative or its salt, which are then subjected to deprotection of the amino group and the sulfur atom, and hydrolysis.

Abstract: The present invention relates to a method for producing optically active IHOG, which can in turn be used for the production of monatin. The present invention further relates to a method for producing optically active monatin, and aldolase used for these methods. As such, the present invention enables the synthesis of 4-(Indole-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid with high optical purity, which is useful as an intermediate in the synthesis of optically active monatin, from indole pyruvic acid and pyruvic acid (or oxaloacetic acid).

Abstract: Disclosed are a novel hydantoin racemase and a process for producing an optically active N-carbamylamino acid or an optically active amino acid using the hydantoin racemase. A novel hydantoin racemase isolated and purified from Bacillus sp. Strain KNK519HR; a gene encoding the hydantoin racemase; a recombinant plasmid having the gene introduced therein; a transformant having the hydantoin racemase gene introduced therein; and a process for producing an optically active N-carbamylamino acid or an optically active amino acid characterized in that a 5-substituted hydantoin compound is treated in the presence of hydantoinase and N-carbamylamino acid amidohydrolase as well as the hydantoin racemase.

Abstract: The present invention relates to 17-oxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies.

Abstract: The present invention relates to a process for preparing a compound II or a composition comprising the compound II to a composition comprising succinimide and to a composition prepared by the process according to the invention

Abstract: The present invention relates to a method for producing optically active IHOG, which can in turn be used for the production of monatin. The present invention further relates to a method for producing optically active monatin, and aldolase used for these methods. As such, the present invention enables the synthesis of 4-(Indole-3-ylmethyl)-4-hydroxy-2-oxoglutaric acid with high optical purity, which is useful as an intermediate in the synthesis of optically active monatin, from indole pyruvic acid and pyruvic acid (or oxaloacetic acid).

Abstract: There is provided a novel method for producing an optically active succinimide compound which is a useful compound utilized as an intermediate raw material for pharmaceutical products or the like. The method for producing an optically active succinimide compound of formula (2) comprises processing a racemic compound of a succinimide compound of formula (1) in the presence of a hydrolase to selectively hydrolyze one of the enantiomers, and subjecting to a post-treatment.